Acs Fall 2024 Vvd-130037 Vvd130037a. The bms team sought to develop a celmod® for ck1α. Trial participants will have a histologically confirmed metastatic or unresectable solid tumor.

(vividion), announced today that it has initiated dosing of patients in a. Vvd130037 dose escalation for solid tumors clinical trial 2023 power, vividion has already.